JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Aandelen Lijst・FibroGen Inc

Search

FibroGen Inc

Gesloten

SectorGezondheidszorg

8.28 -2.47

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.18

Max

8.77

Belangrijke statistieken
By Trading Economics
Inkomsten	-13M 4.6M
Verkoop	126M 2.7M
Winstmarge	169.368
Werknemers	225
EBITDA	77M -14M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+192.77% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	28M
Vorige openingsprijs	10.75
Vorige sluitingsprijs	8.28

Nieuwssentiment

By Acuity

100%

0%

364 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

0.306 / 0.33939 Steun & Weerstand

FibroGen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 feb 2025, 11:34 UTC

Acquisities, Fusies, Overnames

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 feb 2025, 11:34 UTC

Acquisities, Fusies, Overnames

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 feb 2025, 11:33 UTC

Acquisities, Fusies, Overnames

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 feb 2025, 11:33 UTC

Acquisities, Fusies, Overnames

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 feb 2025, 11:31 UTC

Acquisities, Fusies, Overnames

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 feb 2025, 11:30 UTC

Acquisities, Fusies, Overnames

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Peer Vergelijking

Prijswijziging

FibroGen Inc Prognose

Koersdoel

By TipRanks

192.77% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.5 USD 192.77%

Hoogste 43 USD

Laagste 8 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor FibroGen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan FibroGen Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.306 / 0.33939Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

364 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

JNJ

Johnson and Johnson

173.89

ABBV

AbbVie Inc

198.28

AZN

AstraZeneca PLC ADR

74.06

NVS

Novartis AG

118.5

ABT

Abbott Laboratories

131.52